Converse Modulation of IRP1 and IRP2 by Immunological Stimuli in Murine RAW 264.7 Macrophages*

Cécile BoutonDagger , Leonor OliveiraDagger , and Jean-Claude DrapierDagger §

From the Section de Recherche, U 365 INSERM, Institut Curie, 26, rue d'Ulm, 75005 Paris, France

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Iron regulatory proteins (IRP1 and IRP2) are two cytoplasmic RNA-binding proteins that control iron metabolism in mammalian cells. Both IRPs bind to specific sequences called iron-responsive elements (IREs) located in the 3' or 5' untranslated regions of several mRNAs, in particular mRNA encoding ferritin and transferrin receptor. In this study, we followed in parallel the in vivo regulation of the two IRPs in physiologically stimulated macrophages. We show that stimulation of mouse RAW 264.7 macrophage-like cells increased IRP1 IRE binding activity 4-fold, whereas IRP2 activity decreased 2-fold 8 h after interferon-gamma /lipopolysaccharide treatment. Decrease in IRP2 was not due to nitric oxide (NO) production and did not require de novo protein synthesis. Our data therefore indicate that the two IRPs can be conversely regulated in response to the same stimulus. In addition, the effect of endogenously produced NO on IRP1 was further characterized in an activated macrophage/target cell system. We show that NO acts as an intercellular signal to increase IRP1 activity in adjacent cells. As the effect was detectable within 1 h and did not require de novo protein synthesis, this result supports a direct action of NO on IRP1.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Iron regulatory proteins (IRP1 and IRP2)1 are cytoplasmic trans-regulators that modulate expression of several mRNA containing one or several regulatory sequences in their untranslated regions termed iron-responsive elements (IREs) (1, 2). An IRE has been located at the 5' end of the mRNA of ferritin H- and L-chain and erythroid 5-aminolevulinate synthase and, as revealed more recently, on mitochondrial aconitase and subunit b of Drosophila melanogaster succinate dehydrogenase mRNA (3-8). IRE/IRP interaction in the 5' untranslated region inhibits mRNA translation (9-14). Five IRE sequences have also been located in the 3' untranslated region of transferrin receptor mRNA and, in that case, IRE/IRP interaction confers stability against endonucleolytic cleavage (15, 16). Thus, IRPs control uptake, storage, and intracellular metabolism of iron through their IRE binding activity.

Two IRPs called IRP1 and IRP2 have been characterized and cloned in several cell types (12, 17, 18). IRP1 exhibits considerable sequence homology with mitochondrial aconitase and has been identified as the cytoplasmic aconitase (19-21). The two activities of this protein are mutually exclusive. The form that presents aconitase activity converting citrate into isocitrate in the cytosol possesses an intact 4Fe-4S cluster, whereas the IRE-binding form lacks it (22, 23). Thus, the status of the Fe-S cluster is crucial to determination of IRP1 function. In iron-repleted cells, holoIRP1 predominates and exhibits aconitase activity. Conversely, apoIRP1, which binds IRE with high affinity, is the major form in iron-depleted cells. This first discovered regulation of IRP1 by iron led to the suggestion that a switch between the holo- and apoprotein without any change in IRP1 protein levels explains the regulation (2). In vitro, IRP2 binds IRE sequences of ferritin and transferrin receptor (Tf-R) mRNA with similar affinity to IRP1 (17, 24). This second IRP shares 61% amino acid identity with IRP1, but despite conservation of the cluster-ligating cysteines at the active site, IRP2 is unable to assemble an Fe-S cluster in vitro and therefore is unable to exhibit aconitase activity (25). The primary sequences of IRPs principally differ from each other by the insertion of a 73-amino acid sequence in the N terminus domain of IRP2. It has been shown that this cysteine-rich sequence is required to regulate IRP2 expression by iron (26). Unlike the regulation of IRP1 by iron, loss of IRE binding of IRP2 is due to its own degradation via the proteasome pathway (26, 27). Despite the rising interest in IRP2 displayed for the last few years, the questions as to why two IRPs exist and about their respective roles are still puzzling.

Apart from the regulation mediated by iron availability, NO was the first physiological molecule found to be able to convert IRP1 from aconitase to the IRE-binding form in macrophages and non-macrophage cells (28, 29). It has also been established that endogenous NO production was able to repress ferritin mRNA translation and to stabilize transferrin receptor mRNA (30). IRP1 activation has also been reported in fibroblasts (Ltk-) exposed to H2O2 and chemicals able to release NO (31). The effect of H2O2 is fast and indirect and, in contrast to our previous proposal (32) it was stated that the effect of NO is slow and analogous to that exhibited by iron chelators (31). In the same set of experiments, it was shown that IRP2 of fibroblasts Ltk- also exhibited higher IRE binding activity after treatment by NO-releasing drugs (31). These results conflicted with those published by another group showing that neither endogenous NO production by the hepatoma cell line FTO2B nor its exposure to exogenous NO influences the IRE binding activity of IRP2 (33).

To clarify the regulation of the two IRPs by NO (or congeners), we have first studied the modulation of their IRE binding activity in RAW 264.7 macrophages immunologically stimulated for NO production. We show that endogenous TNF is required for NO-dependent activation of IRP1 RNA binding activity. Further, we report that unlike IRP1, IRP2 loses its IRE binding activity independently of the production of NO. We have also carefully investigated the time course of the effect of NO on aconitase and IRE binding activities of IRP1 in an effector/target coculture system. We show that NO released by macrophages quickly modulates IRP1 activities of target cells without requirement of de novo synthesis of protein.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Reagents-- Murine recombinant interferon-gamma (specific activity: 2 × 107 units/mg) was produced by Genentech and provided by Dr G. R. Adolf (Boehringer Ingelheim, Vienna, Austria). Rabbit anti-TNF-alpha antibodies (neutralizing titer was 1 to 25,000) were produced in our laboratory by repeated inoculations of rabbits with pure Mu-rTNF. NG-monomethyl-L-arginine, Escherichia coli lipopolysaccharide (serotype 0111: B4), cycloheximide, and desferrioxamine were purchased from Sigma.

Macrophage and C58 Pre-T Cell Lines-- The macrophage cell line RAW 264.7 was obtained from the American Type Culture Collection and cultured at 37 °C in a 5% CO2 atmosphere in high glucose Dulbecco's modified Eagle's medium supplemented with 5% endotoxin low fetal calf serum. The rat C58 pre-T cell line was kindly supplied by Dr. Markus Nabholz (Institut Suisse de Recherches Experimentales sur le Cancer, Epalinges, Switzerland) and cultured in RPMI supplemented with 10% endotoxin low fetal calf serum and 5 mM glutamine. RAW 264.7 cells were stimulated with IFN-gamma alone or in combination with LPS. When indicated, 1 mM NG-monomethyl-L-arginine, 100 µM desferrioxamine, or a rabbit anti-TNF-alpha antibody was added to the culture medium.

Cell Cocultures-- RAW 264.7 macrophages were stimulated for 16 h with 10 units/ml IFN-gamma and 50 ng/ml LPS for NO synthase 2 (NOS2) induction. Cells were exhaustively washed with phosphate-buffered saline to remove the stimulating agents. Under these conditions, it has been shown that macrophages are able to produce NO for 24 h without further stimuli. Pre-T C58 target cells were added to the NO-producing macrophage monolayers at an effector to target ratio of 1. When required, release of the NOS2 products was blocked by addition of 1 mM NG-monomethyl-L-arginine, and de novo protein synthesis was inhibited by 800 ng/ml cycloheximide.

Preparation of Cell Extracts-- Cells (1 × 106/ml) were treated with 0.007% digitonin for 10 min at 4 °C in 0.25 M sucrose, 100 mM HEPES, pH 7.2, to lyse cells without damaging mitochondria. The resulting lysate was then centrifuged at 75,000 rpm for 20 min in a Beckman TL 100 ultracentrifuge to spin down any particulate material. Cytosolic extracts (0.5 mg/ml) were aliquoted and kept at -80 °C until use for gel mobility shift assay and aconitase measurement (34). In some experiments, cells (1 × 106/ml) were also treated with 0.5% Nonidet-P40 for 5 min at room temperature. The lysates were then centrifuged at 10,000 × g for 15 min at 4 °C. Supernatants were directly analyzed for gel mobility shift assay or kept at -80 °C.

Gel Mobility Shift Assay-- IRP/IRE interactions were measured as described previously (35, 36) by incubating a molar excess of [32P]CTP-labeled IRE transcript from plasmid pSPT-fer with 5-10 µg of cytoplasmic extracts in a 20 µl reaction volume. After 10 min of incubation at room temperature, 20 units of RNase T1 and 5 mg/ml heparin were sequentially added for 10 min each. IRE-protein complexes were run on a nondenaturing 6% polyacrylamide gel. In parallel experiments, samples were routinely treated with 2% 2-mercaptoethanol prior to addition of the IRE probe to allow full expression of IRE binding activity (37). The IRP-IRE complexes were quantified with a PhosphorImager using Image Quant software (Molecular Dynamics, Sunnyvale, CA). Experiments were performed at least three times, and one representative experiment is shown.

Determination of Aconitase Activity-- Aconitase activity was measured spectrophotometrically by following the disappearance of cis-aconitate at 240 nm as described previously (34, 38). Briefly, the reaction volume (900 µl) contains 60 µg of cytoplasmic extract in 100 mM Tris-HCl pH 7.4, and kinetics was started by the addition of 15 µl of 20 mM cis-aconitate. Units represent nanomoles of substrate consumed/min at 37 °C (epsilon = 3.6 mM-1 cm-1).

Measurement of Nitrite-- The formation of nitrite, one of the end products of nitric oxide, was determined spectrophotometrically in the culture medium at 543 nm, using the Griess reagent containing 0.5% sulfanilamide and 0.05% N-(1-naphthyl)ethylenediamine hydrochloride in 45% acetic acid.

Measurement of Protein Synthesis-- Cells were cultivated with various concentrations of cycloheximide in leucine-starved RPMI medium for 24 h. Then, cells were pulse-labeled with 4 µCi/ml of L-[3H]leucine for 2 h. After incorporation of leucine, cells were washed ten times and harvested in 10% trichloroacetic acid solution. Samples were centrifuged at 10,000 × g for 10 min, and protein pellets were resuspended in 50 µl of 10% trichloroacetic acid. Incorporated 3H-radioactivity was measured as described previously (34). Cell viability was estimated using the LDL-10 kit from Sigma.

Protein Determination-- The protein content of extracts was determined spectrophotometrically at 595 nm, using the Bio-Rad protein assay (Bio-Rad) with bovine serum albumin as standard.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

IRP1 and IRP2 Are Conversely Regulated in Activated RAW 264.7 Macrophages-- As shown previously, IFN-gamma -treated macrophages express NOS2, and release of endogenous NO can be followed by nitrite accumulation in culture medium. As a consequence, IRP1 exhibits high affinity for IRE (28, 29) (Fig. 1, lane 2). Here we show that incubation of cells with anti-TNF-alpha antibodies before treatment with IFN-gamma maintains IRE binding activity of IRP1 at a basal level (Fig. 1, compare lanes 1-3). It is likely that production of endogenous TNF-alpha , by boosting NOS2 expression, allows activation of IRP1 in concert with IFN-gamma . In unstimulated RAW 264.7 cells, IRP2 expresses constitutive basal IRE binding activity as high as that of IRP1 (Fig. 2A, lane 1) and, in agreement with previous data, is markedly enhanced after treatment with 2% 2-ME (39). As expected, in response to overnight stimulation by IFN-gamma , IRE binding activity of IRP1 was increased, but in striking contrast, that of IRP2 decreased and was not fully restored by 2-ME (Fig. 2A, lane 2). Furthermore, when associated with IFN-gamma , LPS, which maximally induces NOS2 in murine macrophages, enhanced IRE binding activity of IRP1 and amplified the loss of IRE binding activity of IRP2 (Fig. 2A, lane 3). As evidenced by PhosphorImaging analysis, activation of IRP1 and inactivation of IRP2 correlated with NO synthesis as measured by nitrite release in the culture medium (Fig. 2B). Despite loading of an identical amount of protein on the gel, we consistently observed that IRE binding activity of IRP1 after addition 2% 2-ME was less in stimulated cells as compared with control cells (Fig. 2A, lower panel, compare lanes 2 and 3 to lane 1).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 1.   Endogenous TNF participates in IFN-gamma -mediated activation of IRP1. RAW 264.7 cells were stimulated with 400 units/ml IFN-gamma alone or with anti-TNF-alpha antibodies. After 18 h, nitrite production was measured in the culture medium of control and treated cells using Griess reagent. Cell cytosols were tested for IRP/IRE binding by electromobility shift assay. In a parallel experiment, cell extracts were treated with 2% 2-ME before binding to a 32P-IRE probe.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   Differential regulation of IRE binding activities of IRP1 and IRP2 in RAW 264.7 macrophages stimulated for NO synthesis by IFN-gamma alone or IFN-gamma /LPS. A, cells were stimulated with 400 units/ml IFN-gamma (lane 2) or with 10 units/ml IFN-gamma and 50 ng/ml LPS (lane 3) for 16 h. Cell extracts were prepared as described under "Experimental Procedures," and equal amounts of protein were analyzed for IRE binding by IRP1 and IRP2 in the presence or absence of 2% 2-ME. B, radioactivity associated with IRE-IRP complexes was quantified by PhosphorImaging. IRP1 activity was expressed as a percentage of the value obtained after exposure to 2% 2-ME, which allows visualization of the total IRE binding activity of IRP1. Signals of IRP2 activity were plotted in arbitrary units. In parallel, nitrite production (a stable oxidation product of NO) was measured in the culture medium using the colorimetric assay based on the Griess reaction.

It is well known that IRP1 and IRP2 activities are enhanced following treatment of cells with the iron chelator, desferrioxamine. To see whether IFN-gamma -mediated down-regulation of IRP2 can influence the iron-dependent pathway, cells were cultured in the presence of both IFN-gamma and desferrioxamine. As shown in Fig. 3, lanes 1-4, IRP2 of RAW 264.7 cells stimulated by IFN-gamma lost the capacity to respond to desferrioxamine regulation.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 3.   Regulation of IRE binding activities of IRPs by desferrioxamine and IFN-gamma in RAW 264.7 macrophages. A, cells were stimulated for 16 h with 100 µM desferrioxamine (D), 400 units/ml IFN-gamma (gamma ), or a combination of both (D/gamma ). IRE binding activities of IRPs were assayed in cell cytoplasmic extracts in the presence (lanes 5-8) or absence (lanes 1-4) of 2% 2-ME, with an excess of 32P-labeled IRE probe as described under "Experimental Procedures." B, radioactivity associated with IRE-IRP2 complexes was quantified by PhosphorImaging and expressed as described in the legend for Fig. 1.

To clarify the mechanism by which immunological stimuli modulate IRP2, we investigated the kinetics of IRP2 modulation in IFN-gamma /LPS-treated cells in parallel to that of IRP1. When IRE binding of IRP1 exhibited nearly a 4-fold increase after 8 h of treatment, IRP2 activity decreased 2-fold. Converse modulation of both IRPs occurred as soon as NOS2 was expressed as testified by nitrite production. In parallel experiments, we routinely treated cytoplasmic extracts with 2% 2-ME prior to the binding step to fully express the IRE binding activity of both IRPs. We observed that full binding activity of both IRPs of IFN-gamma /LPS-treated cells decreased from the first hour (Fig. 4, compare lanes 1-7 with 8-14). To determine if decrease in IRP2 IRE binding activity was due to NO production, IFN-gamma - or IFN-gamma /LPS-treated RAW 264.7 macrophages were stimulated in the presence of L-NMA, a NOS inhibitor. As shown in Fig. 5, reduction of NO production led to a decrease in IRP1 binding to IRE but had no effect on IRP2 activity. However, as a competitive inhibitor, L-NMA was unable to completely inhibit expression of NOS2 as indicated by residual nitrite production. Because IRP2, at least in RAW 264.7 cells, is more sensitive to post-translational redox modulation than IRP1 (39), we cannot exclude the possibility at this stage that low output of NO is sufficient to down-regulate IRP2. To see whether modulation of IRP2 activity requires de novo protein synthesis, we assessed IRP modulation in IFN-gamma /LPS-treated cells in the presence of cycloheximide, a translation inhibitor. In the presence of cycloheximide, stimulated cells did not produce significant amounts of nitrite before 24 h (Fig. 6A). Under these conditions, IRP1 IRE binding activity was not increased whereas that of IRP2 decreased to the same extent as in cells stimulated in the absence of cycloheximide (Fig. 6B). From these two sets of experiments, we conclude that IRP2 expression or activity is affected in response to immunological stimuli, i.e. IFN-gamma and LPS, independently of NO.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 4.   Time-course effect of RNA binding activities of IRP1 and IRP2 in RAW 264.7 macrophage cell line stimulated by IFN-gamma and LPS. Cells were grown in the presence (lanes 8-14) or absence (lanes 1-7) of 10 units/ml IFN-gamma and 50 ng/ml LPS for 1-24 h. A, NO production was measured by assaying nitrite in culture supernatants of stimulated and unstimulated cells. B, cell extracts were prepared as described under "Experimental Procedures," and equal amounts of protein (3 µg) were treated with or without 2% 2-ME before incubation with a 32P-labeled IRE probe and electrophoresis of the RNA-protein complexes on a 6% native polyacrylamide gel. As signals given by IRP2 are weaker than those of IRP1 in RAW 264.7 cells, they were amplified 7.5 times relative to those of IRP1.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 5.   IRE binding activities of IRP1 and IRP2 in RAW 264.7 macrophages stimulated in the presence of a NOS inhibitor. RAW 264.7 macrophages were exposed for 16 h to 400 units/ml IFN-gamma (left panel) or to 10 units/ml IFN-gamma and 50 ng/ml LPS (right panel) in the presence or absence of 1 mM L-NMA. NO production was measured by assaying nitrite in culture supernatants of stimulated and unstimulated cells. Cytoplasmic extracts were prepared as described under "Experimental Procedures" and tested for IRE binding activities of IRP1 and IRP2 by electromobility shift assay in the presence or absence of 2% 2-ME.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of cycloheximide on IRE binding activities of IRP1 and IRP2 in IFN-gamma /LPS-stimulated RAW 264.7 cells. Cells were stimulated for 1-24 h with 10 units/ml IFN-gamma and 50 ng/ml LPS in the presence or absence of 800 ng/ml cycloheximide (CHX) A, NO production was measured by assaying nitrite in the culture medium of stimulated and control cells using the Griess reagent. B, cell extracts were prepared as described under "Experimental Procedures," and equal amounts of protein (3 µg) were treated with or without 2% 2-ME before performing an RNA binding assay. Signals of IRP2 were 10-fold amplified relative to those of IRP1.

Activation of IRP1 by NO Proceeds by a Fast Response Mechanism-- In a previous paper (28), we showed that kinetics of IRP1 activation in primary macrophages is superimposable on that of endogenous NO production, which suggested that NO (or some species derived from NO) reacts rapidly and directly with IRP1. Yet results of another study (31) indicated that NO exerts a delayed response on IRP1 activity and may therefore affect iron availability rather than targeting the protein. Accordingly, to shed light on this controversial matter, we reinvestigated this question in greater detail. To avoid the lag necessary to induce NOS2 activity, we performed a coculture study. First, macrophages were maximally activated for NO production for 18 h and after exhaustive washings C58 lymphoma target cells, which are unable to produce NO, were added to the macrophage monolayer. RNA binding activity of C58 target cells was then measured versus time. Significant induction of IRE binding activity of IRP1 appeared in C58 cells within 1 h (Fig. 7A) and was correlated with release of nitrite from effector cells (Fig. 7B, upper panel). Meanwhile aconitase activity of IRP1 rapidly decreased in response to NO production (data not shown). In fact, IRP2 expression, which was low at the beginning of cell culture, progressively increased and was maximal after 8 h (see Fig. 7, A and B, lower panel). Interestingly, we noted that IRP2 expression in C58 cells cocultured with NO-releasing macrophages, but in the absence of immunological stimuli, was unchanged (Fig. 7B, lower panel). As expected, IRE binding by IRP1 in target cells was prevented when the macrophage monolayer was cultured in the presence of L-NMA, and notable aconitase activity was measured (Fig. 8). However, induction of IRP1 IRE binding activity was unaffected in the presence of cycloheximide, showing that modulation of IRP1 did not require de novo protein synthesis (Fig. 8).


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 7.   Modulation of IRE binding activity of IRP1 in C58 pre-T cells cocultured with RAW 264.7 macrophages. A, RAW 264.7 cells were cultured for 16 h in the absence or presence of a combination of 10 units/ml IFN-gamma and 50 ng/ml LPS for 18 h to maximize expression of NOS2. These cells were then washed to remove IFN-gamma and LPS before adding C58 cells. C58 cells were cocultivated for 1-16 h with "washed" activated (A) or control (C) RAW 264.7 cells. Cytoplasmic extracts of C58 cells were prepared as described under "Experimental Procedures" and assayed for IRE binding in the presence or absence of 2% 2-ME. B, radioactivity associated with IRE-IRP1 and IRE-IRP2 complexes of C58 cells previously cocultured with control or activated RAW 264.7 cells was quantified by PhosphorImaging and expressed as described in the legend to Fig. 1. Nitrite production was measured in culture medium using Griess reagent.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 8.   IRE binding activity of IRP1 in C58 cells after coculture with NO-producing RAW 264.7 cells in the presence of cycloheximide (CHX) or NOS2 inhibitor. C58 cells were cocultivated for 5 h with control (C) or NO-producing (A) RAW 264.7 macrophages previously washed to remove IFN-gamma and LPS, in the absence (lane 3) or presence (lane 4) of 800 ng/ml cycloheximide or in the presence of 1 mM L-NMA (lane 5). Cytoplasmic extracts of C58 cells were prepared, and equal amounts of protein were analyzed for aconitase and IRE binding activities of IRP1.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Two cytoplasmic proteins, IRP1 and IRP2, have a key role in the regulation of iron metabolism in mammals, by binding specifically to stem-loop structures of several mRNAs. IRP1 is an Fe-S protein whose RNA-binding activity is regulated post-translationally in response to environmental signals: intracellular iron level, nitric oxide synthesis, oxidative stress, and degree of phosphorylation (1, 2, 40, 41). Recent evidence indicates that IRP2 is also regulated by iron but by a different mechanism. Indeed, in response to iron accumulation, IRP2 is degraded via the proteasome pathway (26, 42). In this paper, we report that physiological stimulation of macrophages modulates RNA binding activity of IRP1 and IRP2 conversely. As shown earlier, the pathway that allows cytokines to modulate IRP1 activity relies on NO synthesis. IFN-gamma is a major positive regulator (28, 29), whereas interleukin-4 and interleukin-13 down-regulate IRP1 RNA binding activity (43). In this report, we show that endogenous production of TNF, an important autocrine inducer of NO synthase, is crucial for IFN-gamma -mediated activation of IRP1. It is likely that the part played by inflammatory cytokines in iron availability has far reaching implications for cell-mediated responses to microbial infections or to oxidative stress.

Whether or not immunological stimuli like cytokines can also drive IRP2 is still an open question. Indeed, conflicting results have been reported concerning the effect of NO on IRP2 (31, 33). It has been reported that exposure of fibroblasts to NO-releasing drugs increases RNA binding activity of IRP2, whereas an independent study concluded that endogenous production of NO by hepatoma cells or their treatment by exogenous NO does not have any effect on IRP2 (31, 33). To perform this study, we deliberately chose two cell lines that express significant basal IRP2 activity, i.e. murine RAW 264.7 macrophages and rat lymphoma C58 cells. In RAW 264.7 cells, we observed that in contrast to IRP1, IRP2 activity dropped upon exposure to IFN-gamma . It is noteworthy that this effect was strong enough to counteract the up-regulation of IRP2 classically observed in cells depleted of iron after desferrioxamine treatment.

As IRP2 possesses redox-active cysteines (25, 39, 44), which, as previously pointed out by our group and others, are crucial for its activity (39, 40, 45), it was expected that NO would be the effector molecule responsible for the down-regulation. However, our coculture system clearly demonstrated that IRP2 is controlled independently of NO endogenously produced by macrophages. Overall, these results are reminiscent of data reported by Phillips et al. (33) showing that endogenous NO released by IFN-gamma /LPS-stimulated hepatoma cells does not activate IRP2. However, this is the first report that IRP1 and IRP2 are regulated in opposite ways.

As reported by Schalinske and Eisenstein (40), RNA binding capacity of IRP2 may depend on phosphorylation. Indeed, in HL-60 premonocytic cells, phosphorylation of IRP2 stabilizes a reduced (i.e. active) form, and as a consequence, Tf-R mRNA level is increased (40). It is therefore possible that a modification of the kinase/phosphatase balance within cells could favor formation of a latent form of IRP2 under our experimental conditions. Alternatively, the down-regulation of IRP2 in activated macrophages described in this paper may be due to accelerated degradation of the protein. We also point out that translation inhibition, in IFN-gamma /LPS-stimulated cells, prevents IRP1 activation without altering loss of IRP2 activity. This result stresses an intrinsic role of IRP2 in cells and suggests that IFN-gamma /LPS regulation is not mediated by iron because iron-dependent degradation of IRP2 generally requires de novo protein synthesis (12, 26, 46). Altogether, these results are in keeping with a recent observation showing that in cells lacking IRP1, IRP2 can mediate IRE-dependent regulation of cellular iron by itself (47).

Our observation that immunological/inflammatory stimuli decrease RNA binding by IRP2 may reconcile some published divergent data. Indeed, cells exposed to NO-releasing drugs or overexpressing NO synthase logically exhibit higher expression of Tf-R mRNA (31, 33, 48, 49). Yet it was also reported in the same papers that cells stimulated by IFN-gamma and LPS, despite production of endogenous NO and subsequent activation of IRP1, unexpectedly exhibited a low Tf-R mRNA level (31, 33). The most likely interpretation of these data was that some ill-defined negative effect on Tf-R mRNA expression resulting from immunological stimulation, overcomes the effect of the NO/IRP1 pathway. Besides, Cairo and Pietrangelo (50) using an experimental model of inflammation have reported that IRP2 rather than IRP1 is responsible for modulation of Tf-R mRNA stabilization (50). At this juncture, it is difficult to understand how IRP2 could out-compete IRP1 in binding Tf-R IREs. One simple explanation is that an active IRE-binding form of IRP2 is more abundant in some tissues. If NOS2 is not induced in these tissues, IRP2 activity may prevail. Response would thus be tissue-specific. An alternative interpretation is that IRP2 exhibits greater affinity for Tf-R IREs. A previous report (12) addressed this question and revealed that both IRPs bind Tf-R IRE B and C equally well at least in vitro. However, to our knowledge such data are not available for the three other Tf-R IREs, and it is worth noting that IRP2 has a greater affinity than IRP1 for IREs with an adenine in the middle of the 6-membered loop, i.e. NNGAGN (51, 52). Among the 5 IREs of Tf-R, only IRE A possesses an adenine at this critical position (2, 53). It is therefore tempting to speculate that binding of IRE A by IRP2 is determinant for Tf-R mRNA stabilization. If so, the IFN-gamma /LPS-dependent down-regulation of IRP2 that we reported would explain why Tf-R mRNA expression is decreased in cells exposed to these stimuli (31, 33).

In addition, our study solves a longstanding question as to whether NO rapidly reacts with IRP1 or alternatively affects iron availability and prevents IRP1 cluster reconstitution after a lag (31). Our findings show that IRP1 of cells placed in contact with NO-producing macrophages is significantly activated in less than 1 h. In this short time frame, 15% of IRP1 was completely converted from a form unable to bind IRE into one which can. This means that the biochemical NO-dependent process that activates the protein was completed. Whether it affects all or some of the IRP1 molecules is of secondary importance in this matter and may depend on experimental conditions. The results of this in vivo study thus strengthens our proposal that NO affects IRP1 directly, probably by reacting with its Fe-S cluster. This is in line with recent results of in vitro studies showing that NO in the absence of oxygen yields an EPR-detectable signal typical of iron-nitrosyl complexes in mitochondrial aconitase and IRP1 (54). With NO, cells therefore possess an efficient effector molecule ready to control IRP1 functions and adjust iron availability. The only delay may arise from the requirement to induce NOS2. However, this drawback can be bypassed if one of the constitutive NO synthases (NOS1 and NOS3) is concerned, as already shown in neurons (55) or in the case of closeness to NOS2-expressing cells, as shown in our coculture model.

    ACKNOWLEDGEMENT

We are grateful to Dr. L. C. Kühn, Institut Suisse de Recherches Experimentales sur le Cancer, Epalinges, Switzerland for providing the pSPT-fer plasmid containing the IRE of human ferritin H-chain.

    Note Added in Proof

While this manuscript was being reviewed, an opposite response of IRP1 and IRP2 in IFN-gamma /LPS-activated J774 macrophages was reported (Recalcati, S., Taramelli, D., Coute, D., and Cairo, G. (1998) Blood 91, 1059-1066).

    FOOTNOTES

* This work was supported in part by Grant 6689 from the Association pour la Recherche contre le Cancer.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Institut de Chimie des Substances Naturelles, CNRS, Avenue de la Terrasse, 91190 Gif-sur-Yvette, France.

§ To whom correspondence should be addressed. Tel.: 33-1-69-82-45-62; Fax: 33-1-69-07-72-47; E-mail: Jean-Claude.Drapier@icsn.cnrs- gif.fr.

1 The abbreviations used are: IRP, iron regulatory protein; 2-ME, 2-mercaptoethanol; IFN-gamma , interferon-gamma ; IRE, iron-responsive element; NO, nitric oxide; Tf-R, transferrin receptor; TNF, tumor necrosis factor; LPS, lipopolysaccharide; NOS, NO synthase; L-NMA, NG-mono- methyl-L-arginine.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Hentze, M. W., and Kühn, L. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8175-8182[Abstract/Free Full Text]
  2. Klausner, R. D., Rouault, T. A., and Harford, J. B. (1993) Cell 72, 19-28[Medline] [Order article via Infotrieve]
  3. Aziz, N., and Munro, H. N. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 8478-8482[Abstract]
  4. Cox, T. C., Bawden, M. J., Martin, A., and May, B. K. (1991) EMBO J. 10, 1891-1902[Abstract]
  5. Dandekar, T., Stripecke, R., Gray, N. K., Goossen, B., Constable, A., Johansson, H. E., and Hentze, M. W. (1991) EMBO J. 10, 1903-1909[Abstract]
  6. Hentze, M. W., Caughman, S. W., Rouault, T. A., Barriocanal, J. G., Dancis, A., Harford, J. B., and Klausner, R. D (1987) Science 238, 1570-1573[Medline] [Order article via Infotrieve]
  7. Kohler, S. A., Henderson, B. R., and Kühn, L. C. (1995) J. Biol. Chem. 270, 30781-30786[Abstract/Free Full Text]
  8. Zheng, L., Kennedy, M. C., Blondin, G. A., Beinert, H., and Zalkin, H. (1992) Arch. Biochim. Biophys. 299, 356-360[Medline] [Order article via Infotrieve]
  9. Bhasker, C. R., Burgiel, G., Neupert, B., Emery-Goodman, A., Kühn, L. C., and May, B. K. (1993) J. Biol. Chem. 268, 12699-12705[Abstract/Free Full Text]
  10. Goossen, B., Caughman, S. W., Harford, J. B., Klausner, R. D., and Hentze, M. W. (1990) EMBO J. 12, 4127-4133
  11. Gray, N. K., and Hentze, M. W. (1994) EMBO J. 13, 3882-3891[Abstract]
  12. Guo, B., Yu, Y., and Leibold, E. A. (1994) J. Biol. Chem. 269, 24252-24260[Abstract/Free Full Text]
  13. Melefors, Ö., Goossen, B., Johansson, H. E., Stripecke, R., Gray, N. K., and Hentze, M. W. (1993) J. Biol. Chem. 268, 5974-5978[Abstract/Free Full Text]
  14. Walden, W. E., Patino, M. M., and Gaffield, L. (1989) J. Biol. Chem. 264, 13765-13769[Abstract/Free Full Text]
  15. Binder, R., Horowitz, J. A., Basilion, J. P., Koeller, D. M., Klausner, R. D., and Harford, J. B. (1994) EMBO J. 13, 1969-1980[Abstract]
  16. Casey, J. L., Di Jeso, B., Rao, K., Klausner, R. D., and Harford, J. B. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 1787-1791[Abstract]
  17. Henderson, B. R., Seiser, C., and Kühn, L. C. (1993) J. Biol. Chem. 268, 27327-27334[Abstract/Free Full Text]
  18. Samaniego, F., Chin, J., Iwai, K., Rouault, T., and Klausner, R. D. (1994) J. Biol. Chem. 269, 30904-30910[Abstract/Free Full Text]
  19. Hentze, M. W., and Argos, P. (1991) Nucleic Acids Res. 19, 1739-1740[Abstract]
  20. Kennedy, M. C., Mende-Mueller, L., Blondin, G. A., and Beinert, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11730-11734[Abstract]
  21. Rouault, T. A., Stout, C. D., Kaptain, S., Harford, J. B., and Klausner, R. D. (1991) Cell 64, 881-883[Medline] [Order article via Infotrieve]
  22. Beinert, H., and Kennedy, M. C. (1993) FASEB J. 7, 1442-1449[Abstract/Free Full Text]
  23. Haile, D. J., Rouault, T. A., Tang, C. K., Chin, J., Harford, J. B., and Klausner, R. D. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7536-7540[Abstract]
  24. Kim, H. Y., Klausner, R. D., and Rouault, T. A. (1995) J. Biol. Chem. 270, 4983-4986[Abstract/Free Full Text]
  25. Phillips, J. D., Guo, B., Yang, Y., Brown, F. M., and Leibold, E. A. (1996) Biochemistry 35, 15704-15714[CrossRef][Medline] [Order article via Infotrieve]
  26. Iwai, K., Klausner, R. D., and Rouault, T. A. (1995) EMBO J. 14, 5350-5357[Abstract]
  27. Guo, B., Phillips, J. D., Yu, Y., and Leibold, E. A. (1995) J. Biol. Chem. 270, 21645-21651[Abstract/Free Full Text]
  28. Drapier, J. C., Hirling, H., Wietzerbin, J., Kaldy, P., and Kühn, L. C. (1993) EMBO J. 12, 3643-3649[Abstract]
  29. Weiss, G., Goossen, W. D., Fuchs, D., Pantopoulos, K., Werner-Felmayer, G., Wachter, H., and Hentze, M. W. (1993) EMBO J. 12, 3651-3657[Abstract]
  30. Pantopoulos, K., and Hentze, M. W. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1267-1271[Abstract]
  31. Pantopoulos, K., Weiss, G., and Hentze, M. W. (1996) Mol. Cell. Biol. 16, 3781-3788[Abstract]
  32. Bouton, C., Raveau, M., and Drapier, J. C. (1996) J. Biol. Chem. 271, 2300-2306[Abstract/Free Full Text]
  33. Phillips, J. D., Kinikini, D. V., Guo, B., and Leibold, E. A. (1996) Blood 87, 2983-2992[Abstract/Free Full Text]
  34. Drapier, J. C., and Hibbs, J. B., Jr. (1986) J. Clin. Invest. 78, 790-797[Medline] [Order article via Infotrieve]
  35. Leibold, E. A., and Munro, H. N. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 2171-2175[Abstract]
  36. Müllner, E. W., Neupert, B., and Kühn, L. C. (1989) Cell 58, 373-382[Medline] [Order article via Infotrieve]
  37. Hentze, M. W., Rouault, T. A., Harford, J. B., and Klausner, R. D. (1989) Science 244, 357-359[Medline] [Order article via Infotrieve]
  38. Drapier, J. C., and Hibbs, J. B., Jr. (1996) Methods Enzymol. 269, 26-36[Medline] [Order article via Infotrieve]
  39. Bouton, C., Hirling, H., and Drapier, J. C. (1997) J. Biol. Chem. 272, 19969-19975[Abstract/Free Full Text]
  40. Schalinske, K. L., and Eisenstein, R. S. (1996) J. Biol. Chem. 271, 7168-7176[Abstract/Free Full Text]
  41. Eisenstein, R. S., Tuazon, P. T., Schalinske, K. L., Anderson, S. A., and Traugh, J. A. (1993) J. Biol. Chem. 268, 27363-27370[Abstract/Free Full Text]
  42. Guo, B., Brown, F. M., Phillips, J. D., Yu, Y., and Leibold, E. A. (1995) J. Biol. Chem. 270, 16529-16535[Abstract/Free Full Text]
  43. Weiss, G., Bogdan, C., and Hentze, M. W. (1997) J. Immunol. 158, 420-425[Abstract]
  44. Schalinske, K. L., Anderson, S. A., Tuazon, P. T., Chen, O. S., Kennedy, M. C., and Eisenstein, R. S. (1997) Biochemistry 36, 3950-3958[CrossRef][Medline] [Order article via Infotrieve]
  45. Cairo, G., Tacchini, L., Pogliaghi, G., Anzon, E., Tomasi, A., and Bernelli-Zazzera, A. (1995) J. Biol. Chem. 270, 700-703[Abstract/Free Full Text]
  46. Henderson, B. R., and Kühn, L. C. (1995) J. Biol. Chem. 270, 20509-20515[Abstract/Free Full Text]
  47. Schalinske, K. L., Blemings, K. P., Steffen, D. W., Chen, O. S., and Eisenstein, R. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10681-10686[Abstract/Free Full Text]
  48. Domachowske, J. B., Rafferty, S. P., Singhania, N., Mardiney, M., III, and Malech, H. L. (1996) Blood 88, 2980-2988[Abstract/Free Full Text]
  49. Oria, R., Sanchez, L., Houston, T., Hentze, M. W., Liew, F. Y., and Brock, J. (1995) Blood 85, 2962-2966[Abstract/Free Full Text]
  50. Cairo, G., and Pietrangelo, A. (1995) Eur. J. Biochem. 232, 358-363[Abstract]
  51. Butt, J., Kim, H. Y., Basilion, J. P., Cohen, S., Iwai, K., Philpott, C. C., Altschul, S., Klausner, R. D., and Rouault, T. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4345-4349[Abstract/Free Full Text]
  52. Henderson, B. R., Menotti, E., and Kühn, L. C. (1996) J. Biol. Chem. 271, 4900-4908[Abstract/Free Full Text]
  53. Theil, E. (1994) Biochem. J. 30, 1-11
  54. Kennedy, M. C., Antholine, W. E., and Beinert, H. (1997) J. Biol. Chem. 272, 20340-20347[Abstract/Free Full Text]
  55. Jaffrey, S. R., Cohen, N. A., Rouault, T. A., Klausner, R. D., and Snyder, S. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12994-12998[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.